Neurocrine Biosciences NBIX Business Segments — Cost of revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's business segments — cost of revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's business segments — cost of revenues?
- Neurocrine Biosciences (NBIX) reported business segments — cost of revenues of $13.8M in Q1 2026.
- How has Neurocrine Biosciences's business segments — cost of revenues changed year-over-year?
- Neurocrine Biosciences's business segments — cost of revenues increased by 50.0% year-over-year, from $9.2M to $13.8M.
- What is the long-term trend for Neurocrine Biosciences's business segments — cost of revenues?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — cost of revenues has grown at a 31.0% compound annual growth rate (CAGR), from $23.2M to $52.1M.
- What does business segments — cost of revenues mean?
- Includes the direct costs associated with manufacturing, packaging, and distributing the company's pharmaceutical products. This metric is essential for calculating gross margin and assessing the efficiency of the supply chain.